trending Market Intelligence /marketintelligence/en/news-insights/trending/1kJTUpUuQ3gKJbFk_ZHUdg2 content esgSubNav
Log in to other products


Looking for more?

Contact Us
In This List

Principia Biopharma director dies


Climate Credit Analytics: Linking climate scenarios to financial impacts


Global M&A Infographic Q1 2021


Q1 2021 Global Capital Markets Activity: SPAC IPOs, Issuance in Consumer Discretionary Sector Surge


COVID-19 Impact & Recovery: Private Equity

Principia Biopharma director dies

Principia Biopharma Inc. said one of its directors, Lewis Shuster, has died.

The South San Francisco, Calif.-based company also said it fell out of compliance with the Nasdaq's listing rules as Shuster's death reduced the members of Principia's audit committee to two. The stock market requires listed companies' audit committees to have at least three members.

Principia plans to regain compliance by appointing a new independent director, the company said in a filing.

Principia develops oral therapies for immunology and oncology in the U.S.